After an infection, experts give advice on how to use eye creams correctly.

Published Date: 08 Mar 2023

Following a major outbreak involving the use of tear drops in 13 US states, experts are offering advice on how to protect dry eyes.

Read Full News

Latest News

What Caused the Pigmented Spot on Teen Boy's Eye?

Authors discuss how best to diagnose and manage him, given the absence of any symptoms

The HCPFive: Top News for Healthcare Providers from the Week of 01/25 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

FDA News Recap: Novel Drug Approvals in First Half of 2026

FDA News Recap: Novel Drug Approvals in First Half of 2026

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

FDA Issues Third Reproxalap CRL for Dry Eye Disease

FDA Issues Third Reproxalap CRL for Dry Eye Disease

Todays Updates

AD109 Cuts AHI by 59.6% in Postmenopausal Women With OSA Reena Mehra, MD

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Distinguishing Lambert-Eaton Myasthenic Syndrome From Ocular Myasthenia Gravis in the Eye Clinic Marco Meglio

Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.

PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS Louie Pasculli

The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.

Todays Updates

AD109 Cuts AHI by 59.6% in Postmenopausal Women With OSA Reena Mehra, MD

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Distinguishing Lambert-Eaton Myasthenic Syndrome From Ocular Myasthenia Gravis in the Eye Clinic Marco Meglio

Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.

PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS Louie Pasculli

The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.

Latest News

Authors discuss how best to diagnose and manage him, given the absence of any symptoms

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

FDA News Recap: Novel Drug Approvals in First Half of 2026

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

FDA Issues Third Reproxalap CRL for Dry Eye Disease

News All Time

Consider This Before Cataract Surgery; Grant Rule: What's Next? CDC Nominee Grilled

MedPage Today reporters offer further insights into recently covered topics

New Agents for AMD Preserve Vision, Dramatically Reduce Treatment Burden

Bispecific antibody fares well against faricimab, two gene therapies extend treatment intervals

Vision Benefits in GA With Complement Inhibitor, Regardless of AMD, Anti-VEGF

Largest effects seen in eyes with GA and AMD, dual treatment with pegcetacoplan, VEGF inhibitor

Anti-VEGF Continuous Delivery Device Preserves Vision, Retinal Anatomy in DME

Similar results in patients who had port delivery system for 4 years or switched after 64 weeks

Dramatic Results Seen With Gene Therapy for Age-Related Macular Degeneration

Stable vision and retinal anatomy for up to 5 years, no supplemental therapy for up to 2 years

Drugs for Dry AMD Linked to Thickening of Retinal Nerve

More questions than answers, including whether the thickening is neuroprotective or pathologic

Stem Cell Therapy for GA Shows Early Evidence of Vision Gains, Retina Preservation

ASP7317 may offer potential to improve vision and repair retina, not just slow down atrophy

Branded Bevacizumab Approved for Wet AMD

Approval follows 20 years of off-label use of compounded formulations of the VEGF inhibitor

Use of PDE5 Inhibitor Tied to Increased Glaucoma Risk

Findings add to existing evidence linking the drug class to ophthalmic conditions

Medicare's Paying Less for Cataract Surgery. Ophthalmologists Are Turning to Lasers.

— Doctors typically charge $1,000 to $3,000 per eye for use of the laser

Medicare Is Paying Less for Cataract Surgery

Medicare pays doctors about $520 for a standard cataract procedure, down about 20% in the past decade.

EyePoint's Drug for Age-related Eye Disease Fails Late-stage Trial, Shares Tank

EyePoint said its experimental drug missed the main goal in a late-stage trial as a few patients lost vision ⁠from causes unrelated to the targeted disease, sending its...

Massage Matches Clinic Probing for Infant Tear Duct Blockage

Gently massaging the tear sacs of infants with blocked tear ducts may be as effective as clinic-based probing for clearing tearing and discharge, a noninferiority trial finds.

Can Dexamethasone Drops Prevent Retinal Disease in Preemies?

Dexamethasone eye drops administered in premature infants with early-stage retinal disease appear to reduce the odds of progression to treatment-requiring disease.

Urinary Drug Tadalafil Linked to Glaucoma Risk

Men taking tadalafil for lower urinary tract symptoms face a 22% higher risk of developing glaucoma than those who do not take the drug, a new study finds.

Study Links Uveitis to Higher Risk for Psychiatric Illness

Noninfectious uveitis is linked to higher rates of psychiatric comorbidities, with Black patients most affected, a new study finds.

Recommended News For You

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

Eliminating the SRC-3 gene in immune cells causes an efficient, long-lasting anti-cancer response.

Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus

New research demonstrates a method for screening people at high risk for pancreatic cancer.

Research has shown that Ga-68 FAPI PET enhances pancreatic cancer detection and staging.

High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination

Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients

Recommended Articles For You

Transformative Frameworks in Oncology for Better Care 

Innovative Breakthroughs in Hematology for Modern Medicine 

National Blood Health Promotion Strategies: Evidence-Based Approaches for Improved Outcomes 

Unlocking the Mysteries of ICD 10 Code Normocytic Anemia 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Three out of ten breast cancers detected between screenings, study finds

2.

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

3.

Belzutifan Plus Pembro Approved for Adjuvant RCC

4.

enhancing survivors of brain tumors' quality of life.

5.

The hidden costs of cancer for young survivors are derailing their financial futures

1.

Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers

2.

Pediatric Cancer Cell Metabolism During Development

3.

Risk Assessment of Cancer-Associated Thrombotic Events

4.

Hematopoietic Immune Microenvironment Plasticity: Mechanisms, Clinical Implications, and Emerging Therapeutics

5.

Comprehensive Updates in Hematology and Quality Improvement

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Navigating the Complexities of Ph Negative ALL - Part IX

2.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

4.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

5.

How Advances in Cancer Research Are Improving Treatment Options

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot